UNITED STATES SECURITIES AND EXCHANGE COMMISSION ----------------------
FORM 3 Washington, D.C. 20549 | OMB APPROVAL |
|---------------------|
| OMB Number: |
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES | 3235-0104 |
| Expires: |
| November 30, 2011 |
| Estimated average |
| burden hours per |
| response 0.5 |
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section -----------------------
17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the
(Print or Type Responses) Investment Company Act of 1940
---------------------------------------------------------------------------------------------------------------------------------
|1. Name and Address of | 2.Date of Event |3. Issuer Name and Ticker or Trading Symbol |
| Reporting Person* | Requiring | |
| | Statement | |
| | (Month/Day/Year)| |
|Kowalsky Matthew Paul |04-29-2024 |ENANTA PHARMACEUTICALS INC ENTA |
|-----------------------------------------| |--------------------------------------------------------------------|
| (Last) (First) (Middle) | |4. Relationship of Reporting Person(s) to |5. If Amendment, Date |
| | | Issuer (Check All Applicable) | Original Filed |
| | | | (Month/Day/Year) |
|C/O ENANTA PHARMACEUTICALS, INC.,500 ARSE| | _____ Director _____ 10% Owner | |
|NAL STREET | | | |
|-----------------------------------------| | |-------------------------|
| (Street) | | __X__ Officer _____ Other |6. Individual or |
| | | | Joint/Group Filing |
|WATERTOWN,MA 02472 | | (give title below) (specify below) | (Check Applicable Line) |
| (City) (State) (Zip) | |Chief Legal Officer | _X_ Form filed by One |
| | | |Reporting Person |
| | | | ___ Form filed by More |
| | | |Than One Reporting Person|
---------------------------------------------------------------------------------------------------------------------------------
Table I -- Non-Derivative Securities Beneficially Owned
-----------------------------------------------------------------------------------------------------------------------
| 1. | 2. | 3. | 4. |
| Title of Security (Instr. 4) | Amount of Securities | Ownership Form: | Nature of Indirect Beneficial |
| | Beneficially Owned | Direct (D) or | Ownership (Instr. 5) |
| | (Instr. 4) | Indirect (I) | |
| | | (Instr. 5) | |
-----------------------------------------------------------------------------------------------------------------------
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this
form are not required to respond unless the form displays a currently
valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
-----------------------------------------------------------------------------------------------------------------
|1. | 2. | 3. |4. |5. |6. |
|Title of Derivative Security | Date | Title and |Conversion |Ownership |Nature of |
| (Instr. 4) | Exercisable | Amount of |or Exercise|Form of |Indirect |
| | and Expira- | Underlying |Price of |Derivative |Beneficial |
| | tion Date | Securities |Derivative |Security: |Ownership |
| | (Month/Day/ | (Instr. 4) |Security |Direct(D) or |(Instr. 5) |
| | Year) | | |Indirect (I) | |
| |------------------------|------------------| |(Instr. 5) | |
| | | | |Amount or | | | |
| | | | |Number | | | |
| |Date |Expiration | |of | | | |
| |Exercisable |Date |Title |Shares | | | |
-----------------------------------------------------------------------------------------------------------------
+----------------------------------------------------------------------------------+
| | Relationships |
| Reporting Owner Name / Address +----------+----------+----------+-------- -+
| | Director |10% Owner | Officer | Other |
+--------------------------------------+----------+----------+----------+----------+
|Kowalsky Matthew Paul | . | . |Chief Lega| |
| | | |l Officer | |
|C/O ENANTA PHARMACEUTICALS, INC. | | | | |
|500 ARSENAL STREET | | | | |
|WATERTOWN MA 02472 | | | | |
|--------------------------------------+----------+----------+----------+----------|
Explanation of Responses:
No securities are beneficially owned
Remarks:
Exhibit 24 Power of Attorney filed herewith.
Signatures
/s/ Matthew Paul Kowalsky / 05-01-2024
------------------------------------------------------------- -----------
** Signature of Reporting Person Date
* If the form is filed by more than one reporting person, seeInstruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
POWER OF ATTORNEY
Know all by these presents that the undersigned hereby constitutes and appoints
each of Jay R. Luly, Paul J. Mellett, Stacie Aarestad
and Ryan Rourke Reed, or each of them acting individually, the undersigned's
true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned a Form ID application to be
filed with the Securities and Exchange Commission to obtain EDGAR codes for the
undersigned;
(2) execute for and on behalf of the undersigned Forms 3, 4, and 5 with respect
to the securities of Enanta Pharmaceuticals, Inc. (the "Company") in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;
(3) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form ID
application or Form 3, 4, or 5, complete and execute any amendment or
amendments thereto, and timely file such forms with the United States
Securities and Exchange Commission and any stock exchange or similar authority;
and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 30th day of April, 2024.
/s/ Matthew Paul Kowalsky
Matthew Paul Kowalsky